Anti-PDs and Neuroleptics Flashcards

1
Q

Describe dopamine synthesis

A
  • L-Tyrosine is converted by tyrosine hydroxylase to L-DOPA
  • DOPA is converted by DOPA decarboxylase to Dopamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe dopamine metabolism

A
  • Dopamine transporter (DAT) and Noradrenaline transporter (NET) both are reuptake transporters that reuptake dopamine from the synapse back into the presynaptic neurone and once here they are metabolised / degraded
  • 3 enzymes are involved in the metabolism / degradation:
  1. Monoamine oxidase A (MAO-A): metabolises DA, NE, 5-HT
  2. Monoamine oxidase B (MAO-B): metabolises DA
  3. Catechol-O-methyl transferase (COMT): wide distribution, metabolises all catecholamines
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the 4 dopaminergic pathways - describe the pathways and a brief word on their function? Also, what disease states are they important in?

A
  1. Nigrostriatal pathway - cell bodies of the nerve are present within the subtantia nigra pars compacta (SNc), and the nerves project up to the striatum. Inhibition of these neurones is important in Parkinson’s Disease
  2. Mesolimbic pathway - cell bodies are located in the Ventral Tegmental Area (VTA) and the axons project up to the Nucleus Accumbens (NAcc). This is the brain reward pathway. Important in schizophrenia
  3. Mesocortical pathway - cell bodies are located in the Ventral Tegmental Area (VTA) and the axons project up to the cerebrum. Involved in executive function and complex behavioural patterns. Important in schizophrenia
  4. Tuberoinfundibular pathway - cell bodies in the arcuate nucleus → projection to the median eminence. Regulates prolactin secretion. Inhibition results in hyperprolactinaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the pathophysiology of Parkinson’s Disease

A
  • Severe loss of dopaminergic neurones in the nigrostriatal tract
  • Lewy bodies and neurites found within neuronal cell bodies and axons respectively
  • Consist of abnormally phosphorylated neurofilaments, ubiquitin & α-synuclein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the clinical symptoms of Parkinson’s Disease - the 3 types of symptoms and the symptoms within these

A
  1. Motor symptoms - resting tremor, bradykinesia, rigidity, postural instability
  2. Autonomic nervous system effects - olfactory deficits, orthostatic hypotension, constipation
  3. Neuropsychiatric - sleep disorders, memory deficits, depression, instability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are lewy bodies and lewy neurites, where are they located, and what are their roles in the pathophysiology of parkinson’s disease?

A
  • Lewy bodies are located in the cell bodies
  • Lewy neurites are located in the axons and dendrites
  • These consist of phosphorylated neurofilaments, ubiquitin and α-synuclein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

1) What is the Parkinson’s Disease treatment by dopamine replacement - the name of the drug and its adjuncts? How does this work? No need to describe the basis for these adjuncts yet in this flashcard - it’s in another flashcard
2) What are some side effects seen with this treatment?

A

1)

  • Levodopa + carbidopa (+selegiline)
  • This is centrally decarboxylated into dopamine to replace the missing dopamine in the nigrostriatal pathway

2)

  • Dyskinesias
  • ‘On-and-off treatment’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Name the dopamine replacement therapy commonly used to treat Parkinson’s disease and give the adjuncts given alongside this and the purpose that these serve

A
  • Levodopa
  • You give L-DOPA with DOPA decarboxylase inhibitors: Carbidopa
    • These do not cross the BBB → prevent peripheral conversion of levodopa but not levodopa in the CNS
    • Therefore they reduce required levodopa dosage AND importantly…
    • They reduce triggering of the CTZ so prevents nausea and vomiting
  • COMT inhibitors: Entacapone & Tolcapone
  • MAO-B inhibitors: Selegiline
  • Both reduce metabolism of the levodopa to reduce its clearance in order to prolong its effect
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the use of dopamine receptor agonists in treatment of Parkinson’s Disease

What are the 2 types of this type of treatment and give 2 example drugs of these. Also what are the side effects of one of these types?

A

1)

  • Dopamine receptor agonists activate the dopamine receptors which is useful because dopamine is low in Parkinson’s (as there is loss of dopaminergic neurones in the nigrostriatal pathway)

2)

  1. Ergot derivatives - Bromocriptine and Pergolide
    * SIDE FX: Cardiac fibrosis and increased risk of valvular disease
  2. Non-ergot derivatives - Ropinirole and Rotigotine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which receptors do dopamine act on?

A
  • D1,5(Gs linked)
  • D2-4 (Gi-linked) receptor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

1) Describe the use of MAO-B inhibitors in treatment of Parkinson’s Disease
2) Name 2 anti-PD example drugs that do this

A

1)

  • Remember that one of the enzymes that metabolises dopamine after it has undergone reuptake is MAO-B - it metabolises dopamine
  • So by inhibiting this, you are increasing the amount of dopamine

2)

  1. Selegiline
  2. Rasagiline
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the pathophysiology of…..

1) Positive schizophrenia symptoms
2) Negative schizophrenia symptoms

What are the symptoms of…..

3) Positive schizophrenia symptoms
4) Negative schizophrenia symptoms

A

1)

  • Increased mesolimbic activity

2)

  • Decreased mesocortical activity

3)

  • Hallucinations - auditory and visual
  • Delusions - paranoia
  • Thought disorder - self-denial

4)

  • Affective flattening - lack of emotion
  • Alogia: lack of speech
  • Avolition / apathy - loss of motivation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the 2 first generation anti-psychotics used to treat schizophrenia?

A
  1. Chlorpromazine
  2. Haloperidol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

1) What type of drug is Chlorpromazine, what is it used to treat, and what is its mode of action?
2) What are its side effects?

A

1)

  • First generation anti-psychotic
  • Treats positive schizophrenia symptoms
  • D2 receptor antagonist

2)

  • Anti-cholinergic effects, especially sedation
  • Extra-pyramidal side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

1) What type of drug is Haloperidol and what is it used to treat? What is its mode of action?
2) What are some of the side effects of Haloperidol?

A

1)

  • First generation anti-psychotic
  • Treats positive schizophrenia symptoms
  • D2 antagonist

2)

  • Extra-pyramidal side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

1) What are the first generation anti-psychotics, what are their modes of action, and what are they used to treat?
2) Why are they useful in treating this, but not in treating the other form of this condition (also what are these conditions)?

A

1)

  • Chlorpromazine
  • Haloperidol
  • They are both D2 receptor antagonists
  • They are used to treat positive schizophrenia symptoms

2)

  • They are useful in treating positive schizophrenia symptoms because this is to do with increased mesolimbic activation - so decreasing dopamine transmission is useful for this
  • They are not useful, and may even make things worse in negative schizophrenia symptoms because this is to do with decreased mesocortical activation - so decreasing dopamine transmission may depress this activation further
17
Q

What are the 4 second generation anti-psychotics used to treat schizophrenia?

A
  1. Clozapine
  2. Risperidone
  3. Quetiapine
  4. Aripiprazole
18
Q

1) What type of drug is Clozapine? What is its mode of action? What is it used to treat?
2) What are the side effects of clozapine use?

A

1)

  • Second generation anti-psychotic
  • 5-HT2A receptor antagonist
  • Also has actions on H1 receptors and alpha-1 receptors, and inhibits the dopamine D2 receptors
  • Treats negative schizophrenia and resistant schizophrenia

2)

  • Potentially fatal neutropenia and agranulocytosis
  • Myocarditis
  • Weight gain
19
Q

1) What type of drug is Risperidone? What is its mode of action? What is it used to treat?
2) What are the side effects of Risperidone use - explain one of these side effects?

A

1)

  • Second generation anti-psychotic
  • Potent antagonists of 5-HT2A and D2 receptors
  • Treats Schizophrenia

2)

  • Extra-pyramidal side effects
  • Hyperprolactinaemia - because the antagonisation of D2 receptors can occur to depress the transmission in the temperoinfundibular pathway - so causes increases prolactin secretion
20
Q

1) What type of drug is Quetiapine? What is its mode of action? What is it used to treat?
2) What are the side effects of Quetiapine use - why is it good in terms of side effects?

A

1)

  • Second generation anti-psychotic
  • H1 receptor antagonist
  • Treats Schizophrenia

2)

  • Some extra-pyramidal side effects but less so than other anti-psychotics
21
Q

1) What type of drug is Aripiprazole? What is its mode of action? What is it used to treat?
2) What are the side effects of Aripiprazole use - why is it good in terms of side effects?

A

1)

  • Second generation anti-psychotic
  • Partial agonist of 5-HT2A and D2 receptors
  • TREATS BOTH positive and negative schizophrenia symptoms
  • Because if there is too much activity (in the mesolimbic pathway - positive schizophrenia) the partial agonist activity actually acts as an inhibitor
  • If there is too little activity (in the mesocortical pathway - negative schizophrenia) the partial agonist activity increases activity to treat this

2)

  • Some hyperprolactinaemia and weight gain but…..
  • Good because there is less hyperprolactinaemia than with other anti-psychotics because there is no depression of transmission in the temperoinfundibular pathway